| Improved survival in multiple myeloma and the impact of novel therapies SK Kumar, SV Rajkumar, A Dispenzieri, MQ Lacy, SR Hayman, FK Buadi, ... Blood, The Journal of the American Society of Hematology 111 (5), 2516-2520, 2008 | 2808 | 2008 |
| Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients SK Kumar, A Dispenzieri, MQ Lacy, MA Gertz, FK Buadi, S Pandey, ... Leukemia 28 (5), 1122-1128, 2014 | 1519 | 2014 |
| Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma P Moreau, T Masszi, N Grzasko, NJ Bahlis, M Hansson, L Pour, I Sandhu, ... New England Journal of Medicine 374 (17), 1621-1634, 2016 | 1234 | 2016 |
| Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements S Kumar, A Dispenzieri, MQ Lacy, SR Hayman, FK Buadi, C Colby, ... Journal of Clinical Oncology 30 (9), 989-995, 2012 | 1116 | 2012 |
| A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma DS Siegel, T Martin, M Wang, R Vij, AJ Jakubowiak, S Lonial, S Trudel, ... Blood, The Journal of the American Society of Hematology 120 (14), 2817-2825, 2012 | 810 | 2012 |
| Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013 JR Mikhael, D Dingli, V Roy, CB Reeder, FK Buadi, SR Hayman, ... Mayo Clinic Proceedings 88 (4), 360-376, 2013 | 692 | 2013 |
| Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma MQ Lacy, SR Hayman, MA Gertz, A Dispenzieri, F Buadi, S Kumar, ... Journal of Clinical Oncology 27 (30), 5008-5014, 2009 | 421 | 2009 |
| Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines SK Kumar, JR Mikhael, FK Buadi, D Dingli, A Dispenzieri, R Fonseca, ... Mayo Clinic Proceedings 84 (12), 1095-1110, 2009 | 384 | 2009 |
| Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics S Kumar, R Fonseca, RP Ketterling, A Dispenzieri, MQ Lacy, MA Gertz, ... Blood, The Journal of the American Society of Hematology 119 (9), 2100-2105, 2012 | 328 | 2012 |
| Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death E Muchtar, MA Gertz, SK Kumar, MQ Lacy, D Dingli, FK Buadi, M Grogan, ... Blood, The Journal of the American Society of Hematology 129 (15), 2111-2119, 2017 | 303 | 2017 |
| Remission of disseminated cancer after systemic oncolytic virotherapy SJ Russell, MJ Federspiel, KW Peng, C Tong, D Dingli, WG Morice, ... Mayo Clinic proceedings 89 (7), 926-933, 2014 | 303 | 2014 |
| Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1β-induced interleukin 6 production and the myeloma … JA Lust, MQ Lacy, SR Zeldenrust, A Dispenzieri, MA Gertz, TE Witzig, ... Mayo Clinic Proceedings 84 (2), 114-122, 2009 | 302 | 2009 |
| Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease MQ Lacy, JB Allred, MA Gertz, SR Hayman, KD Short, F Buadi, ... Blood, The Journal of the American Society of Hematology 118 (11), 2970-2975, 2011 | 276 | 2011 |
| Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM) MQ Lacy, SR Hayman, MA Gertz, KD Short, A Dispenzieri, S Kumar, ... Leukemia 24 (11), 1934-1939, 2010 | 249 | 2010 |
| Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial MA Dimopoulos, F Gay, F Schjesvold, M Beksac, R Hajek, KC Weisel, ... The Lancet 393 (10168), 253-264, 2019 | 247 | 2019 |
| Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis TV Kourelis, SK Kumar, MA Gertz, MQ Lacy, FK Buadi, SR Hayman, ... Journal of clinical oncology 31 (34), 4319-4324, 2013 | 246 | 2013 |
| Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma KD Short, SV Rajkumar, D Larson, F Buadi, S Hayman, A Dispenzieri, ... Leukemia 25 (6), 906-908, 2011 | 241 | 2011 |
| Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria A Lakshman, SV Rajkumar, FK Buadi, M Binder, MA Gertz, MQ Lacy, ... Blood cancer journal 8 (6), 59, 2018 | 239 | 2018 |
| Randomized trial of lenalidomide versus observation in smoldering multiple myeloma S Lonial, S Jacobus, R Fonseca, M Weiss, S Kumar, RZ Orlowski, ... Journal of Clinical Oncology 38 (11), 1126-1137, 2020 | 237 | 2020 |
| The utility of plasma vascular endothelial growth factor levels in the diagnosis and follow-up of patients with POEMS syndrome A D'Souza, SR Hayman, F Buadi, M Mauermann, MQ Lacy, MA Gertz, ... Blood, The Journal of the American Society of Hematology 118 (17), 4663-4665, 2011 | 234 | 2011 |
